Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.
about
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.A p53 drug response signature identifies prognostic genes in high-risk neuroblastomaNBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest.E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemiaPathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseasesMechanisms of neuroblastoma cell growth inhibition by CARP-1 functional mimetics.Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experimentsWIP1 phosphatase as a potential therapeutic target in neuroblastomaMechanism of N-Acylthiourea-mediated activation of human histone deacetylase 8 (HDAC8) at molecular and cellular levels.NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosisInitial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing ProgramEffect of low doses of actinomycin D on neuroblastoma cell linesCellular Stress and p53-Associated Apoptosis by Juniperus communis L. Berry Extract Treatment in the Human SH-SY5Y Neuroblastoma Cells.Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo.Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.Nutlin-3a selects for cells harbouring TP53 mutations.Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.Identifying novel therapeutic agents using xenograft models of pediatric cancer.Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
P2860
Q27853125-623DC182-F01F-4E6E-9CEA-11E85B91FB97Q28537647-F76ABDA7-CB4F-4431-9A4C-13B009E583E6Q30651336-8C6882E1-604B-4B2F-ADF7-8F331DEEEAC6Q33903412-B0318A84-AB77-48F6-A888-D32C63E2ED7FQ33909288-BAF35BF3-4C4F-4580-9954-2E6EA0C70D59Q33916362-7FEDCE8F-884A-40A8-B173-4C4DD29A55DFQ34972240-7A99902A-0A3B-4F64-AA46-F4EF21F9A8E7Q35058327-A65290A3-EC92-4E57-BBAA-B6B89508EFE5Q35173031-EF07CE33-20BF-4E62-A90B-995E60363BBCQ36022258-129B9633-81D4-436B-B6CF-59EF1630CC01Q36392660-222F28C7-128F-459C-8C6B-5BABEE13E4C3Q36423770-BFBCDBE2-9828-4106-88A9-0E6D5D89A584Q37134608-C4233CB4-97E0-4DD8-9DC2-D18FDCF5B747Q37139011-2BAED0CA-2EE4-4F4F-B429-B439A7DD27EDQ37290519-EACCDCB1-0D29-4313-90E7-3E509196F5C7Q37392937-A37B6D10-1064-4184-94AB-020199852E33Q38625880-B1DE6BA0-ABEE-474F-A7DA-C36D1E826EA8Q38677396-BC4F1D23-2939-4E54-BEE9-7936BF22A581Q38697986-E32C47E5-3340-4AE1-B436-B7366619B502Q38733034-335AD9EF-E26F-49B2-B5CB-E23CB3C27DCEQ38767574-D2E6A2FB-B4C3-4D90-BF6F-BD895B0587B6Q38837564-8AD06633-2C96-4509-B49E-001C69CF2369Q38890690-A3E237A1-1C36-42AC-BF96-25B43BAD8FF9Q38985584-FBADA5DB-F02C-42FC-B1E2-1A5713A181E0Q39051757-186964E4-7654-4D07-8E8E-90B28799EAEFQ39116877-800A6812-52E9-4AFF-A529-97AAE10CDAF6Q39205970-0A139917-2A68-4681-9147-D3C8AD7E301FQ40209862-D79A9460-4E4E-4D3A-96D0-18EC236FD3CCQ40466065-4D169292-265E-472A-AAA5-4EE72E7E6F88Q41343291-41992FE2-90C3-4EEA-938A-26D425F56C93Q42362115-487D3C80-BE0E-4176-8B49-291D55D19404Q48874456-E8A76FE8-E0CA-4EE9-8774-5269AC32795B
P2860
Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Functional analysis of the p53 ...... cule MDM2 antagonist nutlin-3.
@en
Functional analysis of the p53 ...... cule MDM2 antagonist nutlin-3.
@nl
type
label
Functional analysis of the p53 ...... cule MDM2 antagonist nutlin-3.
@en
Functional analysis of the p53 ...... cule MDM2 antagonist nutlin-3.
@nl
prefLabel
Functional analysis of the p53 ...... cule MDM2 antagonist nutlin-3.
@en
Functional analysis of the p53 ...... cule MDM2 antagonist nutlin-3.
@nl
P2093
P50
P1476
Functional analysis of the p53 ...... cule MDM2 antagonist nutlin-3.
@en
P2093
Daniel Dreidax
Frank Westermann
Sarah De Clercq
Tom Van Maerken
P304
P356
10.1158/1535-7163.MCT-10-1090
P577
2011-04-01T00:00:00Z